{"id":14785,"date":"2026-05-08T01:56:52","date_gmt":"2026-05-08T01:56:52","guid":{"rendered":"https:\/\/globalnewstoday.uk\/index.php\/2026\/05\/08\/zura-bio-reports-first-quarter-2026-financial-results-and-recent-corporate-updates-biospace\/"},"modified":"2026-05-08T01:56:52","modified_gmt":"2026-05-08T01:56:52","slug":"zura-bio-reports-first-quarter-2026-financial-results-and-recent-corporate-updates-biospace","status":"publish","type":"post","link":"https:\/\/globalnewstoday.uk\/index.php\/2026\/05\/08\/zura-bio-reports-first-quarter-2026-financial-results-and-recent-corporate-updates-biospace\/","title":{"rendered":"Zura Bio Reports First Quarter 2026 Financial Results and Recent Corporate Updates – BioSpace"},"content":{"rendered":"

HENDERSON, Nev.–(BUSINESS WIRE)–Zura Bio Limited<\/a><\/span> (Nasdaq: ZURA) (\u201cZura\u201d), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced financial results for the first quarter ended March 31, 2026, and provided recent corporate updates.
\u201cWe entered the second quarter with a strengthened balance sheet and strengthened team, reflecting growing conviction in bispecific approaches and increased appreciation for IL\u201117 and BAFF biology\u201d said Sandeep Kulkarni, M.D., Chief Executive Officer of Zura. \u201cWe believe we are well positioned\u2014operationally, financially, and scientifically\u2014as we approach anticipated tibulizumab readouts starting later this year.\u201d
PROGRAM UPDATES<\/b>
Tibulizumab (ZB\u2011106)<\/b>
During the first quarter of 2026, Zura continued to advance its two ongoing Phase 2 studies of tibulizumab, a bispecific antibody designed to neutralize interleukin-17 (IL-17) and B-cell activating factor (BAFF), key mediators of inflammation and fibrosis.
Additionally, Zura is conducting a disciplined evaluation of potential new indications for tibulizumab.
Additional Clinical Stage Product Candidates<\/b>
In addition to tibulizumab, Zura is continuing its evaluation of potential development approaches for torudokimab (ZB\u2011880) and crebankitug (ZB\u2011168), informed by current clinical and translational evidence and ongoing assessment of the evolving competitive landscape.
CORPORATE HIGHLIGHTS<\/b>
In January 2026, Zura appointed Sandeep Kulkarni, M.D., as Chief Executive Officer. In February 2026, Zura appointed Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D., Ph.D., to its Board of Directors. Dr. Eisner, is a seasoned biotechnology executive with over 25 years of leadership in clinical development and immunology and recently served as Executive Vice President and Chief Medical Officer of Vir Biotechnology. Dr. Nirula, is an accomplished physician-scientist and immunology leader who currently serves as president, and head of research and development at Recludix. He previously served as Senior Vice President and Immunology Therapeutic Area Head at Eli Lilly.
In February 2026, Zura closed an underwritten public offering of Class A ordinary shares and pre-funded warrants to purchase Class A ordinary shares, resulting in gross proceeds of approximately $144 million, before deducting underwriting discounts, commissions, and offering expenses. The proceeds are expected to support continued advancement of the Company\u2019s pipeline and broader strategic development initiatives.
FIRST QUARTER 2026 FINANCIAL RESULTS<\/b>
Cash Position<\/b>
As of March 31, 2026, Zura had cash and cash equivalents of $225.6 million. Zura expects that its existing cash and cash equivalents are sufficient to support planned operations through at least the end of 2028.
Research and Development (R&D) Expenses<\/b>
R&D expenses were $14.7 million for the first quarter of 2026, compared to $10.5 million for the first quarter of 2025. The increase was primarily driven by the continued advancement of Zura\u2019s Phase 2 tibulizumab clinical programs.
General and Administrative (G&A) Expenses<\/b>
G&A expenses were $10.8 million for the first quarter of 2026, compared to $8.8 million for the first quarter of 2025. The increase was primarily due to an increase in compensation expense, including share-based compensation and professional fees to support the Company\u2019s growth and advancement of its clinical programs.
Net Loss<\/b>
Net loss for the first quarter of 2026 was $24.2 million, or $0.22 per share, compared to $17.4 million, or $0.19 per share, for the same period in 2025.
ABOUT ZURA<\/b>
Zura is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases with unmet need. Zura\u2019s pipeline includes product candidates designed to target key mechanisms of immune system imbalance, with the goal of improving efficacy, safety, and dosing convenience for patients.
Zura\u2019s lead product candidate, tibulizumab (ZB-106), is being evaluated in two Phase 2 clinical studies in adults: TibuSHIELD, a study in hidradenitis suppurativa (HS), and TibuSURE, a study in systemic sclerosis (SSc). Additional product candidates torudokimab (ZB-880) and crebankitug (ZB-168) have completed Phase 1\/1b studies and are being evaluated for their potential across a range of autoimmune and inflammatory conditions.
For more information, please visit www.zurabio.com<\/a><\/span>.
FORWARD-LOOKING STATEMENTS<\/b>
Any statements contained in this press release that do not describe historical facts may constitute \u201cforward\u2011looking statements\u201d as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words and phrases such as \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cdesigned to,\u201d \u201cexpect,\u201d \u201cgoal,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201coutlook,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cshould,\u201d \u201cwill,\u201d and similar expressions, and are based on Zura\u2019s current beliefs and expectations. These forward\u2011looking statements include, but are not limited to, statements regarding the development and potential therapeutic benefits of Zura\u2019s product candidates; the timing, progress, design and results of Zura\u2019s current and future clinical trials, including the anticipated reporting of data therefrom; the potential to expand Zura\u2019s product candidates into additional indications; the sufficiency of Zura\u2019s cash resources and projected cash runway; and other statements that are not historical facts. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such forward\u2011looking statements. Risks and uncertainties that may cause actual results to differ materially include, but are not limited to: uncertainties inherent in the development of therapeutic product candidates, such as the risk that one or more of Zura\u2019s current or future product candidates may not be successfully developed or commercialized; the risk of delay or cessation of any planned clinical trials of Zura\u2019s current or future product candidates; the risk that prior results, including signals of safety, activity or durability of effect observed in preclinical studies or earlier clinical trials, may not be replicated or may not continue in ongoing or future studies or clinical trials; the risk that modeling data indicating therapeutic potential, or clinical evidence from other drug candidates, may not be predictive of results in Zura\u2019s current or future clinical trials; the risk that Zura\u2019s product candidates or procedures in connection with their administration may not have the safety or efficacy profiles anticipated; risks related to the accuracy of Zura\u2019s estimates of expenses, capital requirements and needs for additional financing; changes in expected or existing competition; changes in the regulatory environment; uncertainties related to the timing and outcome of the regulatory approval process; unexpected litigation or other disputes; the impact of macroeconomic conditions on Zura\u2019s business, clinical trials and financial position; and other risks and uncertainties to be described in Zura\u2019s Annual Report on Form 10\u2011K for the year ended December 31, 2025, and other filings with the Securities and Exchange Commission. Any forward\u2011looking statements speak only as of the date of this press release and are based on information available to Zura as of the date hereof. Zura assumes no obligation to, and does not intend to, update any forward\u2011looking statements, whether as a result of new information, future events or otherwise, except as required by law.
ZURA BIO LIMITED<\/b>
CONSOLIDATED BALANCE SHEETS<\/b>
(In thousands, except share data<\/i>)
 
 
March 31,<\/b>
 
December 31,<\/b>
 
 
2026<\/b>
 
2025<\/b>
 
 
(unaudited)<\/b>
 
 
 
Assets<\/b>
 
 
 
 
 
 
Current assets
 
 
 
 
 
 
Cash and cash equivalents
 
$
225,594
 
 
$
109,407
 
Prepaid expenses and other current assets
 
 
1,410
 
 
 
2,903
 
Total current assets
 
 
227,004
 
 
 
112,310
 
Property and equipment, net
 
 
125
 
 
 
126
 
Other assets
 
 
1,512
 
 
 
1,512
 
Total assets
 
$
228,641
 
 
$
113,948
 
 
 
 
 
 
 
 
Liabilities and Shareholders\u2019 Equity<\/b>
 
 
 
 
 
 
Current liabilities
 
 
 
 
 
 
Accounts payable and accrued expenses
 
$
11,745
 
 
$
12,410
 
Total current liabilities
 
 
11,745
 
 
 
12,410
 
Total liabilities
 
 
11,745
 
 
 
12,410
 
 
 
 
 
 
 
 
Commitments and contingencies
 
 
 
 
 
 
 
 
 
 
 
 
 
Shareholders\u2019 Equity
 
 
 
 
 
 
Class A Ordinary Shares, $0.0001 par value; 300,000,000 shares authorized as of March 31, 2026 and December 31, 2025; 94,880,710 and 73,680,710 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively
 
 
9
 
 
 
 
 
7
 
 
 
Additional paid-in capital
 
 
465,657
 
 
 
326,078
 
Accumulated deficit
 
 
(248,770
)
 
 
(224,547
)
Total shareholders\u2019 equity
 
 
216,896
 
 
 
101,538
 
Total liabilities and shareholders\u2019 equity
 
$
228,641
 
 
$
113,948
 
ZURA BIO LIMITED<\/b>
CONSOLIDATED STATEMENTS OF OPERATIONS<\/b>
(Unaudited)<\/b>
(In thousands, except share and per share data)<\/i>
 
 
For the Three Months Ended<\/b>
 
 
March 31,<\/b>
 
 
2026<\/b>
 
2025<\/b>
Operating expenses:
 
 
 
 
 
 
Research and development
 
$
14,746
 
 
$
10,474
 
General and administrative
 
 
10,753
 
 
 
8,780
 
Total operating expenses
 
 
25,499
 
 
 
19,254
 
Loss from operations
 
 
(25,499
)
 
 
(19,254
)
Other income, net
 
 
 
 
 
 
Interest income
 
 
(1,319
)
 
 
(1,817
)
Other expense, net
 
 
43
 
 
 
5
 
Total other income, net
 
 
(1,276
)
 
 
(1,812
)
Loss before income taxes
 
 
(24,223
)
 
 
(17,442
)
Income tax benefit
 
 
\u2014
 
 
 
\u2014
 
Net loss
 
$
(24,223
)
 
$
(17,442
)
Net loss per share, basic and diluted
 
$
(0.22
)
 
$
(0.19
)
Weighted-average shares outstanding, basic and diluted
 
 
112,222,789
 
 
 
92,964,048
 
 
Investor and media inquiries:
ir@zurabio.com<\/a><\/span>
Get daily news updates when you subscribe to GenePool!
\u00a9 1985 – 2026 BioSpace.com. All rights reserved. <\/p>\n

source<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

HENDERSON, Nev.–(BUSINESS WIRE)–Zura Bio Limited (Nasdaq: ZURA) (\u201cZura\u201d), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced financial results for the first quarter ended March 31, 2026, and provided recent corporate updates. \u201cWe entered the second quarter with […]<\/p>\n","protected":false},"author":1,"featured_media":14786,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[],"class_list":{"0":"post-14785","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-business"},"_links":{"self":[{"href":"https:\/\/globalnewstoday.uk\/index.php\/wp-json\/wp\/v2\/posts\/14785","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/globalnewstoday.uk\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/globalnewstoday.uk\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/globalnewstoday.uk\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/globalnewstoday.uk\/index.php\/wp-json\/wp\/v2\/comments?post=14785"}],"version-history":[{"count":0,"href":"https:\/\/globalnewstoday.uk\/index.php\/wp-json\/wp\/v2\/posts\/14785\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/globalnewstoday.uk\/index.php\/wp-json\/wp\/v2\/media\/14786"}],"wp:attachment":[{"href":"https:\/\/globalnewstoday.uk\/index.php\/wp-json\/wp\/v2\/media?parent=14785"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/globalnewstoday.uk\/index.php\/wp-json\/wp\/v2\/categories?post=14785"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/globalnewstoday.uk\/index.php\/wp-json\/wp\/v2\/tags?post=14785"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}